Record revenue growth of 17% in Q2 and 30% for H1, with improved margins and reduced losses. Acquisition of Pharmacure and Nozoil, strong cash position, and positive clinical results support confidence in reaching profitability by Q4 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.